drugset / Trial / NCT06246968
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
Participants will have a confirmed diagnosis of metastatic breast cancer and will receive pembrolizumab in combination with cryoablation OR pembrolizumab alone. Participants will be randomly assigned.
Timeline
- Start
- 2024-01-29
- Primary completion
- 2027-01-29
- Completion
- 2027-01-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Pembrolizumab | Monoclonal antibody | — | — |